Insys posts loss after founder charged in U.S. opioid bribe case

BOSTON (Reuters) - Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company.